Table 1. Characteristics of the study patients.
| Variable | All patients (n=172) | Patients without PHLF (n=129) | PHLF cohort | P value | ||
|---|---|---|---|---|---|---|
| Grade A group (n=24) | Grade B group (n=14) | Grade C group (n=5) | ||||
| Age (y) | 54±12 | 54±12 | 54±10 | 53±12 | 54±8 | 0.991 |
| Numbers of male patients [%] | 135 [78] | 101 [78] | 21 [88] | 8 [57] | 3 [60] | 0.717 |
| Serum biomarker levels (preoperative results) | ||||||
| TB (μmol/L) | 14.3 [10.8–19.0] | 14.1 [10.6–18.6] | 14.6 [11.0–23.5] | 15.6 [12.0–20.1] | 15.1 [10.9–17.6] | 0.359 |
| AST (U/L) | 32 [32–41] | 31 [25–40] | 38 [27–49] | 31 [24–59] | 42 [33–80] | 0.119 |
| ALT (U/L) | 28 [20–41] | 27 [20–40] | 34 [27–59] | 20 [16–42] | 52 [18–142] | 0.056 |
| Platelet count (109/L) | 131 [84–184] | 130 [84–183] | 137 [96–184] | 112 [50–193] | 157 [127–206] | 0.57 |
| Serum biomarker levels (on/after postoperative day 5) | ||||||
| TB (μmol/L) | 24.9 [18.1–34.6] | 22.5 [16.7–28.7] | 39.9 [33.8–51.6] | 62.1 [39.6–103.4] | 68.7 [54.3–106.4] | <0.0001 |
| INR | 1.13 [1.08–1.21] | 1.12 [1.07–1.16] | 1.20 [1.18–1.39] | 1.24 [1.16–1.48] | 1.35 [1.20–1.93] | <0.0001 |
| Catalogue of liver diseases | ||||||
| Hepatocellular carcinoma | 111 (64.5%) | 88 | 13 | 5 | 5 | |
| Metastatic tumors | 47 (27.3%) | 29 | 10 | 6 | 2 | |
| Benign lesions | 14 (8.2%) | 12 | 1 | 1 | 0 | |
Data were described as means ± standard deviations or medians [interquartile ranges] as appropriate. Patients were divided into No PHLF, PHLF A, B, C groups according to ISGLS criteria, and statistical analysis was conducted for comparison of these 4 groups. TB, total bilirubin; AST, aspartate transaminase; ALT, alanine aminotransferase; INR, international normalized ratio of prothrombin time; ISGLS, International Study Group of Liver Surgery; PHLF, post-hepatectomy liver failure.